Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5%

• Status: Completed
• Trial end date: 2009-03-01
• Target enrollment: 0
• Participant gender: All

Summary

To compare bromfenac 0.09%, diclofenac sodium 0.1%, and ketorolac tromethamine 0.5% ophthalmic solutions for the treatment of acute pseudophakic CME after cataract surgery.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bp Consulting, Inc
• Treatments: Bromfenac; Diclofenac; Ketorolac; Ketorolac Tromethamine

Criteria

Inclusion Criteria:

• Patients must be diagnosed with acute pseudophakic CME within 12 months of cataract surgery

• Males and females 18 years and older

• Able to provide written informed consent

Exclusion Criteria:

• Complicated cataract surgery, particularly posterior capsule rupture and vitreous loss

• Pre-Existing macular pathology, including macular edema, macular scar, macular hole, or macular pucker

• History of Uveitis

• Ipsilateral intraocular surgery prior to cataract surgery

• CME greater than one year duration